罕见病知识库 RareSeen

镰状细胞病及相关疾病

Sickle cell disease

ORPHA:275752疾病组中国目录 第1批 · 106

近两年的全球研究 7,963L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-10
    Exploring the Patient Perspective of Gene Therapy for Sickle Cell Disease
    American journal of hematology · DOI · Europe PMC
  • 2026-10
    Brief Cognitive Assessment in Sickle Cell Care: Psychometric Properties of the RUDAS Across Two Languages
    Blood advances · DOI · Europe PMC
  • 2026-10
    Reframing sickle cell disease care: improving care with an embedded primary care model for chronic comorbidity management
    Expert review of hematology · DOI · Europe PMC
  • 2026-10
    Abstracts
    JPGN reports
  • 2026-10综述开放获取
    Ovarian Reserve in Women of Reproductive Age With Sickle Cell Anaemia: A Scoping Review
    EJHaem · DOI · Europe PMC
  • 2026-10
    Maternal and perinatal outcomes associated with prophylactic erythrocytapheresis in pregnant women with sickle cell disease
    International journal of gynaecology and obstetrics: the official orga · DOI · Europe PMC
  • 2026-10
    Integrating sexual health into sickle cell disease care
    The Lancet. Haematology · DOI · Europe PMC
  • 2026-10
    From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease?
    The Lancet. Haematology · DOI · Europe PMC
  • 2026-10
    Flipping the fetal switch across β-hemoglobinopathies
    Cell stem cell · DOI · Europe PMC
  • 2026-10
    Bimacular Avascular Zone in a Woman Aged 39 Years With Sickle Cell Disease
    JAMA ophthalmology · DOI · Europe PMC
  • 2026-10开放获取
    Small populations, big impact: leveraging rare disease gene therapies to benefit millions
    The Journal of clinical investigation · DOI · Europe PMC
  • 2026-10综述
    Red blood cell transfusion in sickle cell disease: From clinical necessity to immunological complexity
    Transfusion medicine (Oxford, England) · DOI · Europe PMC
  • 2026-10开放获取
    Real-World Claims Data on Prescribed Drugs and the Associated Drug-Drug Interaction Risk in Sickle Cell Disease in the United States
    Clinical and translational science · DOI · Europe PMC
  • 2026-10开放获取
    Teaching Cell and Gene Therapy in Genetic Counseling Programs: Survey Findings and Suggested Practical Resources for Integration
    Journal of genetic counseling · DOI · Europe PMC
  • 2026-10开放获取
    The Role of Ferroptosis Induced by Iron Overload in Osteoblast and Osteoclast Function
    Cell biology international · DOI · Europe PMC
  • 2026-10开放获取
    Kidney Structure and Blood Flow Predict Function and Enable Image-Based eGFR With Non-Contrast MRI
    NMR in biomedicine · DOI · Europe PMC
  • 2026-10
    Decision-Making in IVF: Restrictions on PGT-M Positive Embryo Transfers-A Qualitative Study
    Journal of genetic counseling · DOI · Europe PMC
  • 2026-10综述
    Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children
    The Lancet. Child & adolescent health · DOI · Europe PMC
  • 2026-10
    Predicting Non-Target Neutrophil Collection During HPC(A): Implications for Research Protocols in Apheresis
    Journal of clinical apheresis · DOI · Europe PMC
  • 2026-09开放获取
    Assessing Quality of Life and Associated Factors Among Caregivers of Children With Chronic Conditions at Tamale Teaching Hospital: A Cross-Sectional Study
    Health science reports · DOI · Europe PMC

境外已获批用于本病的药物 8L2

欧盟 2 项、美国 6 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

尚未获批的在研药物(73 项)

这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineen欧盟2005-08-26
    Treatment of sickle cell disease
    官方记录
  • 2,2-Dimethylbutyric acid, sodium salt欧盟2009-03-18
    Treatment of sickle cell disease
    官方记录
  • pegylated carboxyhaemoglobin欧盟2009-11-26
    Treatment of sickle cell disease
    官方记录
  • Deferiprone欧盟2011-02-23
    Treatment of sickle cell disease
    官方记录
  • human haptoglobin欧盟2011-12-09
    Treatment of sickle cell disease
    官方记录
  • human erythrocytes encapsulating inositol hexaphosphate欧盟2012-07-04
    Treatment of sickle cell disease
    官方记录
  • Xyndari欧盟2012-07-04
    Levoglutamide
    Treatment of sickle cell disease
    官方记录
  • sevuparin sodium欧盟2015-02-12
    Treatment of sickle cell disease
    官方记录
  • Oxbryta欧盟2016-11-18
    2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor)
    Treatment of sickle cell disease
    官方记录
  • decitabine;tetrahydrouridine欧盟2017-06-20
    Treatment of sickle cell disease
    官方记录
  • sirolimus欧盟2018-01-17
    Treatment of sickle cell disease
    官方记录
  • Docosahexaenoic acid ethyl ester欧盟2018-03-21
    Treatment of sickle cell disease
    官方记录
  • benserazide hydrochloride欧盟2019-01-11
    The treatment of sickle cell disease
    官方记录
  • Hemopexin欧盟2020-07-27
    Treatment of sickle cell disease
    官方记录
  • (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5欧盟2020-10-19
    Treatment of sickle cell disease
    官方记录
  • 2-(2-{[2-(1h-benzimidazol-2-yl)ethyl]amino}ethyl)-n-[(3-fluoropyridin-欧盟2021-02-19
    Treatment of sickle cell disease
    官方记录
  • autologous CD34+ hematopoietic stem and progenitor cells transfected w欧盟2021-02-19
    Treatment of sickle cell disease
    官方记录
  • Epeleuton欧盟2022-10-11
    Treatment of sickle cell disease
    官方记录
  • nicotinamide mononucleotide欧盟2023-06-20
    Treatment of sickle cell disease
    官方记录
  • tarperprumig欧盟2023-07-25
    Treatment of sickle cell disease
    官方记录
  • mitapivat sulfate欧盟2024-12-13
    Treatment of sickle cell disease
    官方记录
  • nangibotide欧盟2025-11-21
    Treatment of sickle cell disease
    官方记录
  • poloxamer 188 (purified)美国1989-06-27
    Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)
    官方记录
  • Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid美国1991-10-24
    Prophylactic treatment of sickle cell disease.
    官方记录
  • Isobutyramide美国1994-05-25
    Treatment of sickle cell disease and beta thalassemia.
    官方记录
  • Clotrimazole美国1995-04-24
    Treatment of sickle cell disease.
    官方记录
  • Bis(4-fluorophenyl)phenylacetamide美国2000-03-02
    Treatment of sickle cell disease.
    官方记录
  • niprisan美国2003-08-15
    Treatment of sickle cell disease
    官方记录
  • oral unfractionated heparin美国2004-01-29
    Treatment of sickle cell disease
    官方记录
  • 5-hydroxymethyl-2-furfuraldehyde美国2006-05-26
    Treatment of sickle cell disease
    官方记录
  • sodium 2, 2 dimethylbutyrate美国2008-07-25
    Treatment of sickle cell disease.
    官方记录
  • pentosan polysulfate sodium美国2008-11-21
    Treatment of sickle cell disease.
    官方记录
  • (1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate美国2009-02-17
    Treatment of vaso-occlusive crisis in patients with sickle cell disease.
    官方记录
  • pegylated carboxyhemoglobin美国2010-10-21
    Treatment of acute painful sickling crises in patients with sickle cell disease
    官方记录
  • carbon monoxide美国2012-09-28
    Treatment of sickle cell disease
    官方记录
  • extract of sorghum bicolor extract美国2012-11-19
    Treatment of sickle cell disease
    官方记录
  • recombinant humanized IgG1k monoclonal antibody to human invariant T c美国2013-04-12
    Treatment of sickle cell disease
    官方记录
  • human haptoglobin美国2013-11-19
    Treatment of sickle cell disease
    官方记录
  • pegylated carboxyhemoglobin bovine美国2015-01-15
    Treatment of sickle cell disease
    官方记录
  • hydroxyurea美国2015-03-16
    Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.
    官方记录

另有 33 项未列出。

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 7L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

登记为可入组 4

  • 招募中NCT06399107
    Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
    I 期、II 期 · 干预性 · 2024/08/01Essen Biotech
    中国研究中心 1 个:Beijing
  • 招募中NCT06565026
    CS-206 in Patients With Sickle Cell Disease
    早期 I 期 · 干预性 · 2024/09/02CorrectSequence Therapeutics Co., Ltd
    中国研究中心 1 个:Nanning
  • 尚未开始招募NCT07190001
    YOLT-204 in Patients With Hemoglobinopathies
    早期 I 期 · 干预性 · 2025/09/30Guangzhou Women and Children's Medical Center
    中国研究中心 1 个:Guangzhou
  • 尚未开始招募NCT07000318
    CS-206 in Patients With Sickle Cell Disease
    早期 I 期 · 干预性 · 2026/09/30Children's Hospital of Fudan University
    中国研究中心 1 个:Shanghai
其他状态的试验(3 项)
  • 已完成NCT00171821
    A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
    III 期 · 干预性 · 2005/04Novartis Pharmaceuticals
    中国研究中心 3 个:Guangzhou、Nanjing、Shanghai
  • 状态未知NCT06300723
    Clinical Study of BRL-101 in Severe SCD
    不适用 · 干预性 · 2024/07/29Bioray Laboratories
    中国研究中心 1 个:Nanning
  • 已完成NCT06581627
    A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants
    I 期 · 干预性 · 2024/08/26Novo Nordisk A/S
    中国研究中心 1 个:Beijing

中国境外的在招试验 217L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

美国119法国31英国10加拿大9Nigeria8意大利8西班牙8德国7土耳其7Uganda6比利时6埃及5巴西5Kenya5另有 29 个国家/地区

CT.gov 报告命中 217 项,此处取回并展示最近的 15 项。

  • 尚未开始招募NCT07540767
    Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
    不适用 · 干预性 · 2027/09/01Connecticut Children's Medical Center
    美国
  • 尚未开始招募NCT07797582
    MBI for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease
    不适用 · 干预性 · 2027/02University of Illinois at Chicago
  • 尚未开始招募NCT05605366
    Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
    I 期 · 干预性 · 2026/12/01University of Cincinnati
  • 尚未开始招募NCT07530965
    Omega-3-Fatty Acids in Children With Sickle Cell Disease
    不适用 · 干预性 · 2026/12/01University of Alabama at Birmingham
  • 尚未开始招募NCT07648043
    Feasibility and Acceptability of Amani
    I 期、II 期 · 干预性 · 2026/11/01Massachusetts General Hospital
    美国
  • 尚未开始招募NCT07826988
    Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis
    IV 期 · 干预性 · 2026/10/01Assistance Publique - Hôpitaux de Paris
  • 尚未开始招募NCT07799571
    Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
    I 期 · 干预性 · 2026/10Natasha Archer
    美国
  • 尚未开始招募NCT07774351
    A Clinical Exploratory Study of YOLT-204 in the Treatment of Hemoglobinopathies
    不适用 · 干预性 · 2026/09/30Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • 招募中NCT07369024
    Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
    II 期 · 干预性 · 2026/09/10Mohsen Saidinejad
    美国
  • 尚未开始招募NCT07703566
    CPAP for Hypoxemic Acute Chest Syndrome in Sickle Cell Disease
    不适用 · 干预性 · 2026/09/01Assistance Publique - Hôpitaux de Paris
  • 尚未开始招募NCT07782489
    Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP"
    观察性 · 2026/09/01Assistance Publique - Hôpitaux de Paris
  • 尚未开始招募NCT07217548
    Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients
    不适用 · 干预性 · 2026/09/01Ohio State University
    美国
  • 尚未开始招募NCT07802210
    Effectiveness of Innovative Educational Methods in Empowering Children With Sickle Cell Disease
    不适用 · 干预性 · 2026/09/01Aula Ibrahim abd alrazak
    Iraq
  • 尚未开始招募NCT07752043
    Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients
    不适用 · 干预性 · 2026/09Assistance Publique - Hôpitaux de Paris
    法国
  • 招募中NCT07616154
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
    II 期 · 干预性 · 2026/09St. Jude Children's Research Hospital
    美国

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)